Cite
HARVARD Citation
Das, A. et al. (2021). CCN5 activation by free or encapsulated EGCG is required to render triple‐negative breast cancer cell viability and tumor progression. Pharmacology research & perspectives. 9 (2), p. n/a. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Das, A. et al. (2021). CCN5 activation by free or encapsulated EGCG is required to render triple‐negative breast cancer cell viability and tumor progression. Pharmacology research & perspectives. 9 (2), p. n/a. [Online].